Ethan Budin
Managing Director Flexpoint Ford

Ethan is a Managing Director of Flexpoint Ford and the leader of the healthcare practice. Prior to the founding of Flexpoint in 2005, Ethan was a Principal of GTCR focusing on transactions in healthcare, including the formation of CuraScript and the investment in Ovation Holdings. Ethan’s previous positions include: Principal of Leeds Group and its affiliated private equity fund, Advance Capital Partners; Associate with The Boston Consulting Group; and Mergers and Acquisitions Analyst with Lazard Frères and Co.

Ethan graduated with an A.B. in mathematics, summa cum laude, from Harvard University, where he was elected to the Phi Beta Kappa honor society.


Jon Oka
Managing Director Flexpoint Ford

Jon is a Managing Director of Flexpoint Ford. Prior to joining Flexpoint Ford in 2008, Jon served as an Associate at GTCR. Jon has also worked at McKesson Corporation and as a Mergers and Acquisitions Analyst with Lazard Freres and Co. in New York. Jon holds a B.A. from Yale University and an M.B.A. from Harvard Business School.
 


Bryan E. Stuart
President and CEO

Bryan has over 15 years of experience building life sciences companies. He was most recently the Chief Business Officer of Civitas Therapeutics. At Civitas, Bryan was responsible for raising capital, business development, commercial and strategy functions, including the IPO and company sale of Civitas to Acorda Therapeutics (NASDAQ: ACOR). Civitas' lead program, CVT-301, was in P3 clinical trials to treat devastating OFF-episodes associated with Parkinson’s disease. Civitas had raised over $100 million in equity capital from leading venture capital and crossover investors including Wellington, RA Capital, Adage, Orbimed, Sofinnova and Partner Funds amongst others.

Prior to joining Civitas, Bryan served as Chief of Corporate Development at EKR Therapeutics, a biopharmaceutical business focused on the acute care market, which was sold to Cornerstone Therapeutics (NASDAQ: CRTX) in 2012.

Before EKR, he was one of the first members of the management team at Ovation Pharmaceuticals, where he was Vice President of Corporate and Business Development and M&A. Ovation was a biopharmaceutical company focused on the acquisition, development, and commercialization of therapies targeted toward specialty markets and rare diseases. Ovation was built through more than a dozen acquisitions and strategic partnerships and was sold to H. Lundbeck A/S in 2009.

Bryan began his career as a healthcare investment banker for William Blair & Company. He holds a Bachelor of Science in Finance with high honors from the University of Illinois at Urbana-Champaign and a Master of Business Administration from the Kellogg School of Management at Northwestern University.